Swiss imaging software developer Medimaps Group announced it has raised $20 million in financing, which it plans to use to support the commercialization of its artificial intelligence (AI) software for bone health and to expand its product offerings.
The $20 million financing round was led by Swisscanto Invest by Zürcher Kantonalbank. Medimaps said that last November the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a Current Procedural Terminology (CPT) code for its osteoporosis assessment with the company's trabecular bone score (TBS) software. This past July, Medimaps received approval for reimbursement to begin January 1, 2022.
The TBS software provides information about the quality of bone. This has the potential to improve upon traditional bone mineral density measurement, which assesses the quantity of bone, according to the company. A more detailed assessment could help ensure that high-risk patients are diagnosed early, when there is time for intervention, Medimaps said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
